Navigation Links
Clinical Operations Executive, Hassan Movahhed, Joins NDA Partners as Expert Consultant
Date:8/21/2020

NDA Partners Chairman Carl Peck, MD, announced today that Hassan Movahhed, a Clinical Operations executive with expertise in clinical trial planning and feasibility, regulatory inspection readiness, and clinical investigator and CRO management, has joined the firm as an Expert Consultant. Throughout his career, Mr. Movahhed has helped design and manage oncology, neurology, cardiovascular, and anti-infective clinical trials and has prepared for pre-approval regulatory inspections.

Prior to joining NDA Partners, Mr. Movahhed served in Vice President or Senior Vice President roles at several companies including Exelixis, Forty-Seven, Inc., United Therapeutics, Elan, Geron, and Threshold Pharmaceuticals. He was formerly Senior Director and Head of US Development Operations and Clinical Affairs at Amgen and Senior Director of Clinical Operations at ICOS. In his early career, he served in roles of increasing responsibility at Bristol-Myers Squibb in infectious disease clinical research and drug pharmacokinetics and metabolism research.

“Mr. Movahhed’s extensive background in clinical operations will bring great value to our pharmaceutical clients who are conducting clinical trials in a variety of therapeutic areas including oncology, neurology, and cardiology. We are pleased to welcome him to NDA Partners,” said Dr. Peck.

Mr. Movahhed earned a master’s degree in biology and bachelor’s degree in zoology from the University of Michigan.

About NDA Partners
NDA Partners is a life sciences management consulting and contract development organization (CDO) focused on providing product development and regulatory services to the pharmaceutical, biotechnology, and medical device industries worldwide. The highly experienced Principals and Expert Consultants in NDA Partners include three former FDA Center Directors; the former Chief Executive Officer and Chief Science Officer at the United States Pharmacopeial Convention (USP); an international team of more than 100 former pharmaceutical industry and regulatory agency senior executives; and an extensive roster of highly proficient experts in specialized areas including nonclinical development, toxicology, pharmacokinetics, CMC, medical device design control and quality systems, clinical development, regulatory submissions, and development program management. Services include product development and regulatory strategy, expert consulting, high-impact project teams, and contract management of client product development programs.

Contact
Earle Martin, Chief Executive Officer
Office: 540-738-2550
MartinEarle@ndapartners.com

Read the full story at https://www.prweb.com/releases/clinical_operations_executive_hassan_movahhed_joins_nda_partners_as_expert_consultant/prweb17312597.htm.


'/>"/>
Source: PRWeb
Copyright©2020 Vocus, Inc.
All rights reserved


Related biology news :

1. Genetic and clinical factors best to predict late recurrence in estrogen receptor POS breast cancer
2. Clinical Tests Demonstrate Long-Term Effectiveness of Oral Glutathione Supplements - Kyowa Study
3. Elseviers Maturitas publishes clinical guide on endometrial assessment in postmenopausal women
4. Center for Clinical and Translational Science awards new pilot grants
5. Alios BioPharma initiates Phase 1 clinical trial for respiratory syncytial virus infection
6. Inflection Biosciences licenses preclinical oncology programs from the CNIO
7. New sickle cell anemia therapy advances to Phase II clinical trials
8. UCLA stem cell gene therapy for sickle cell disease advances toward clinical trials
9. Damon Runyon Cancer Research Foundation awards $3.6 M to 9 top young clinical investigators
10. With early, obvious benefit of a targeted cancer drug, should expensive clinical testing continue?
11. DO-HEALTH a multi-center clinical trial on healthy ageing achieves first milestone
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/3/2020)... ... September 03, 2020 , ... Litmus ... an extensive third-party assessment of the company’s security practices has been completed. The ... security regulations. The comprehensive evaluation reviewed Litmus’ processes and systems, assessing them to ...
(Date:8/26/2020)... ... August 25, 2020 , ... ... company developing novel pharmaceuticals targeting mitochondria, in partnership with Essex Bio-Technology, a ... its pivotal U.S. Phase 3 VISTA-2 study of SkQ1 ophthalmic solution in ...
(Date:8/26/2020)... (PRWEB) , ... August 25, 2020 , ... Modality ... made Inc. magazine’s 2020 annual Inc. 5000 list. The list is the most prestigious ... in 2019 as well, and for this year’s list, reported three-year revenue growth of ...
Breaking Biology News(10 mins):
(Date:7/1/2020)... Ohio (PRWEB) , ... June 29, 2020 , ... ... offers access to competitively procured purchasing contracts to its membership, recently named ... provide TIPS members with the opportunity to purchase ergonomic seating, cafeteria tables, book ...
(Date:6/28/2020)... ... June 25, 2020 , ... The Indoor Lab, a leading provider ... for businesses of all types to ensure cleanliness, distancing and occupancy with its patent ... Safe Space™ enabled business will provide a health performance index system that scores all ...
(Date:6/28/2020)... ... June 25, 2020 , ... Lumeda Inc. ... cancer, today announced the company has entered a license agreement with Roswell Park ... Lumeda globally exclusive rights to Roswell Park intellectual property surrounding a novel medical ...
(Date:6/23/2020)... (PRWEB) , ... June 23, 2020 , ... ... facilitate access to unique lab-made bioresearch materials, today announced the availability of the ... Whitt laboratory at University of Tennessee, enables studies of SARS-CoV-2 viral entry and ...
Breaking Biology Technology: